1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Endo’s Bleak Financial Reality May See Hope In Spring Amid Potential Restructuring

Generic And Injectables Products Saw Competition And Revenue Decrease

 
• By Urtė Fultinavičiūtė

Endo’s generic and injectable segments struggled last year, with even lower projections for 2024, but potential financial restructuring may help the company rise from the ashes.

Businessman standing front of question mark
• Source: Shutterstock

The struggle is real for Endo. The Dublin-headquartered firm continues to see a drop in financial performance as its generic and injectable products fail to capture the market.

Endo reported a 10% decrease in total net revenues in Q4 2023, making a total of $498m compared to $556m in the same period last year. The decrease was primarily...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

Krka Looks To Kick On In India And China

 
• By Dean Rudge

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

Zydus To Continue Mirabegron Sales

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list.

Sawai Reports ‘Solid Overall’ Full Year Results Despite Some Misses

 
• By Adam Zamecnik

Continuing in its medium-term business plan and company reform, Sawai forecasts its revenue to exceed ¥200bn in the coming fiscal year.

More from Business

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

 
• By Dean Rudge

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.

Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod

 
• By Dave Wallace

Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.